Meta‐analysis finds no increase in suicide risk from use of isotretinoin
Published: (2024)

Review of trials finds psychedelics generally well‐tolerated
Published: (2024)

Antipsychotics linked to reduced suicide risk in patients with schizophrenia
Published: (2025)

Analysis suggests risk of suicidal ideation associated with semaglutide
Published: (2024)

The demise of metformin and the rise of the GLP‐1 agonists
by: Lawrence H. Price
Published: (2026)

Study finds gabapentinoid treatment does not elevate risk of self‐harm
Published: (2025)

Study of children exposed to SSRIs during breastfeeding finds no cognitive risk
Published: (2026)

FDA requests removal of suicide warnings from two GLP‐1 labels
Published: (2026)

Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits
Published: (2025)

Review finds limited benefit from cannabinoids for PTSD
Published: (2024)

Study finds low correspondence between known genetic variations and treatment targets
Published: (2025)

Analysis finds benzodiazepine use in pregnancy linked to higher risk of preterm birth
Published: (2026)

Review finds VMAT‐2 inhibitors promising for treatment of psychosis
Published: (2024)

DBT more efficacious than SSRI in reducing suicidality in borderline personality disorder
Published: (2026)

Postpartum use of dexmedetomidine reduces incidence of depression
Published: (2024)

Trial finds fezolinetant efficacious for vasomotor symptoms in menopause
Published: (2025)

Meta‐analysis finds viloxazine effective for youths with ADHD
Published: (2025)

Study finds association between levonorgestrel exposure, depression
Published: (2024)

Study finds sustained effects of LSD‐assisted therapy on anxiety
Published: (2024)

Study finds no link between prenatal antidepressant exposure and childhood depression
Published: (2025)

Meta‐analysis finds little benefit from cannabinoids for behavioral disorders
Published: (2026)

Network meta‐analysis finds dexmedetomidine broadly effective for postoperative delirium
Published: (2026)

Treatment of late‐life depression improves cognitive function, review finds
Published: (2024)

Survey finds new users of psychedelics report unusual visual experiences
Published: (2024)

Umbrella review finds several ADHD treatments efficacious in short term
Published: (2026)

Head‐to‐head comparison of seven antipsychotics finds olanzapine and risperidone most efficacious
Published: (2026)

Control group improvement lower in psilocybin trials for depression
Published: (2025)

Mixed results for esmethadone in Phase 3 depression trial
Published: (2024)

Researchers recommend training ED physicians on suicide risks in children and teens
by: Alison Knopf
Published: (2024)

Varenicline reduces cannabis use in men in Phase 2 trial
Published: (2026)

Xanomeline‐trospium combination shows strong results in schizophrenia trial
Published: (2024)

Analysis: Study design contributed to differences in ketamine‐ECT trials
Published: (2024)

Psychedelics and psychosis: Quantifying the risk
by: Lawrence H. Price
Published: (2025)

Antimicrobial exposure and risk of depression
by: Y. W. Francis Lam
Published: (2025)

Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia
Published: (2024)

Antipsychotic effects in randomized trials may not reflect real‐world outcomes
Published: (2024)